Clinical Trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06351527
Lead Sponsor InnoCare Pharma Inc.
Conditions Mature B-cell Malignancies
Enrollment 78 participants
Start Date 2024-04-23
Primary Completion 2027-06-25 (estimated)
Study Completion 2027-10-25 (estimated)
Updated on ClinicalTrials.gov 2025-06-19